Navigation Links
Astellas Names Head of Global R&D Operations
Date:6/10/2009

DEERFIELD, Ill., June 10 /PRNewswire/ -- Astellas Pharma Global Development ("APGD"), a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that Dr. Peter Carberry, has been hired as the senior vice president and head of global development operations. Carberry is responsible for enhancing the effectiveness and efficiency of the integrated global operational platform including the data sciences and clinical operations organizations.

"We are pleased that Peter has joined Astellas and we know that he will contribute significantly to the development of innovative products," said Dr. Steven Ryder, president of APGD. "Peter is one of several key hires at APGD that were brought on to strengthen and accelerate our research and development function."

Prior to joining Astellas, Carberry was the vice president of clinical operations, development planning and performance analysis and the office of international development at Genentech. In that role, Carberry developed a global platform for the execution of non-clinical and clinical activities and established many key relationships with company stakeholders. Previously, Carberry was the senior vice president of global clinical operations at Johnson & Johnson Pharmaceutical Research and Development. Dr. Carberry began his industry career with Pharmacia at the Kalamazoo Research site where he held positions of increasing responsibility across the development organization. Carberry earned his M.D. at the University of Nairobi in Kenya and completed his Post Doctoral Fellowship in Clinical Pharmacology at the University of Texas. He earned his M.B.A. at Western Michigan University.

About Astellas

Astellas Pharma Global Development, located in Deerfield, Illinois, is a group company of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. For more information about Astellas Pharma Inc., please visit the website at http://www.astellas.com/en/.


'/>"/>
SOURCE Astellas Pharma Global Development
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Astellas Adds CNS Therapy Area Leader to Global R&D Team
2. Astellas Hires New Vice President of Compliance
3. Astellas Announces New Vice President of Marketing
4. Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
5. Astellas/GlaxoSmithKlines Vesicare Has Advantages Over Pfizers Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
6. FDA Approves Additional Indication for Astellas MYCAMINE(R)
7. Cardiome And Astellas Announce Regulatory Update
8. Spectrum Names Katherine Maynard Chief Operating Officer
9. Sarnova Names Hank Struik Chief Executive Officer
10. Aptium Oncology Names New Chief Operating Officer
11. National Parkinson Foundation Names New Chief Information Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new study by NCPA ... does not obey the rules Congress has directed the CBO to follow. The CBO ... reform would restore. Yet, it estimates a reduction in employer-based coverage due to the ...
(Date:3/24/2017)... ... , ... The iaedp Foundation, the premier provider of educational programs and training ... the full spectrum of disordered eating, announced today that the 2017 Symposium set a ... states and several countries converged on the Green Valley Resort in Las Vegas. ...
(Date:3/24/2017)... ... 24, 2017 , ... Shamanic healer and teacher Anahata Ananda ... Spiritual Awakening, proudly presents her Sacred Peru retreat with world famous shaman ... journey during the Summer Solstice will also be her final international retreat, Anahata ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... wanted to create a communications platform that positions them as the go-to thought ... ONS reinvented their online publication as an always-on, always-fresh news, views and advocacy ...
(Date:3/24/2017)... ... March 24, 2017 , ... On June 9, 2017, ... Claims Litigation seminar in Chicago, Illinois. She will present on: , Filing ... litigated under ERISA involve claims for long-term disability benefits. This session will ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Strategic Business Report" report to their offering. ... The report provides separate comprehensive analytics for the ... Europe , Asia-Pacific , Latin ... provided for the period 2015 through 2022. Also, a six-year historic analysis ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly ... announced plans to invest $850 million in its ... facilities across its U.S. enterprise, including research laboratories, ... investments are being driven by demand for Lilly ... potential medicines in development targeting cancer, pain, diabetes ...
(Date:3/24/2017)... 2017  Mirabilis Medical, a Seattle ... non-invasive surgery, announced today CE Mark authorization for ... uterine fibroids throughout the European Union.  The company ... the US Food and Drug Administration to begin ... the United States.  The Mirabilis System combines high-speed ...
Breaking Medicine Technology: